Comparative Baseline Health-Related Quality of Life in Real-Life Patientswith Monoclonal Gammopathies

Abstract

Health-related quality of life (HRQoL) is increasingly used as a secondary end-point in clinical trials, in particular, in multiple myeloma (MM)-related studies. However, several issues preclude a generalized use. First, the evidence available is still scarce; furthermore, some weaknesses and inconsistencies in analysis and presentation are observed [1]. Second, standardization for data collection, analysis and reporting is lacking. Third, an internationally validated questionnaire should be used.